A Randomized, Double-Blind, Placebo-Controlled Phase Ia First-in-Human Study to Evaluate the Single Intravenous Administration of ISH0613 in Healthy Subjects
Latest Information Update: 07 May 2026
At a glance
- Drugs ISH 0613 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; First in man
- Sponsors SUNHO (China) BioPharmaceutical
Most Recent Events
- 14 Apr 2026 New trial record